Overview Install Files SecuritySummary This source did not publish a separate summary. Review SKILL.md before using the skill.
Drug Development Guide
A comprehensive skill covering the drug development pipeline from target identification through regulatory approval. Designed for pharmaceutical researchers, medicinal chemists, and clinical scientists conducting academic or industry research.
Drug Discovery Pipeline Overview
Target ID -> Hit Finding -> Lead Optimization -> Preclinical -> Phase I -> Phase II -> Phase III -> Regulatory Filing
(1-2 yr) (1-2 yr) (1-3 yr) (1-2 yr) (1 yr) (2 yr) (3 yr) (1-2 yr)
Total timeline: ~10-15 years | Success rate: ~5-10% from Phase I to approval
Estimated cost: $1.3B-$2.8B per approved drug (DiMasi et al., 2016)
Target Identification and Validation
Computational Target Discovery
import pandas as pd
from scipy import stats
def differential_expression_analysis(expression_data: pd.DataFrame,
disease_group: list[str],
control_group: list[str],
fdr_threshold: float = 0.05) -> pd.DataFrame:
"""
Identify differentially expressed genes as potential drug targets.
Args:
expression_data: Gene x Sample expression matrix
disease_group: Sample IDs in disease condition
control_group: Sample IDs in control condition
fdr_threshold: False discovery rate threshold
"""
results = []
for gene in expression_data.index:
disease_vals = expression_data.loc[gene, disease_group]
control_vals = expression_data.loc[gene, control_group]
t_stat, p_value = stats.ttest_ind(disease_vals, control_vals)
fold_change = disease_vals.mean() / (control_vals.mean() + 1e-10)
results.append({
'gene': gene,
'fold_change': fold_change,
'log2_fc': np.log2(abs(fold_change) + 1e-10),
'p_value': p_value,
't_statistic': t_stat
})
df = pd.DataFrame(results)
# Benjamini-Hochberg FDR correction
from statsmodels.stats.multitest import multipletests
df['fdr'] = multipletests(df['p_value'], method='fdr_bh')[1]
df['significant'] = df['fdr'] < fdr_threshold
return df.sort_values('fdr')
Target Validation Criteria A robust drug target should satisfy multiple criteria:
Criterion Method Evidence Strength Genetic association GWAS, Mendelian randomization Strong Expression in disease tissue RNA-seq, immunohistochemistry Moderate Functional role CRISPR knockout, siRNA Strong Druggability Structural analysis, binding pockets Essential Safety (anti-target) Phenotype of loss-of-function mutations Essential
Lead Optimization
ADMET Property Prediction Assess absorption, distribution, metabolism, excretion, and toxicity early:
def lipinski_rule_of_five(molecular_weight: float, logp: float,
hbd: int, hba: int) -> dict:
"""
Evaluate Lipinski's Rule of Five for oral bioavailability.
Args:
molecular_weight: Molecular weight in Da
logp: Calculated LogP (lipophilicity)
hbd: Number of hydrogen bond donors
hba: Number of hydrogen bond acceptors
"""
violations = 0
details = []
if molecular_weight > 500:
violations += 1
details.append(f"MW {molecular_weight} > 500")
if logp > 5:
violations += 1
details.append(f"LogP {logp} > 5")
if hbd > 5:
violations += 1
details.append(f"HBD {hbd} > 5")
if hba > 10:
violations += 1
details.append(f"HBA {hba} > 10")
return {
'violations': violations,
'passes': violations <= 1,
'details': details,
'assessment': 'Likely orally bioavailable' if violations <= 1
else 'Poor oral bioavailability expected'
}
Pharmacokinetics Modeling
Compartmental PK Analysis import numpy as np
from scipy.optimize import curve_fit
def one_compartment_iv(t, dose, V, CL):
"""One-compartment IV bolus model."""
k_el = CL / V
return (dose / V) * np.exp(-k_el * t)
def compute_pk_parameters(time_points: np.ndarray,
concentrations: np.ndarray,
dose: float) -> dict:
"""
Fit one-compartment model and derive PK parameters.
"""
popt, pcov = curve_fit(
lambda t, V, CL: one_compartment_iv(t, dose, V, CL),
time_points, concentrations,
p0=[10, 1], bounds=(0, [1000, 100])
)
V, CL = popt
t_half = 0.693 * V / CL
auc = dose / CL
return {
'volume_of_distribution_L': round(V, 2),
'clearance_L_hr': round(CL, 2),
'half_life_hr': round(t_half, 2),
'AUC_mg_hr_L': round(auc, 2)
}
Clinical Trial Design
Phase Selection and Endpoints Phase Primary Goal Typical N Key Endpoints Phase I Safety, dose finding 20-80 MTD, DLT, PK Phase II Efficacy signal 100-300 ORR, PFS, biomarkers Phase III Confirmatory efficacy 300-3000 OS, PFS, PROs Phase IV Post-marketing surveillance 1000+ ADRs, real-world effectiveness
Always pre-register clinical trials on ClinicalTrials.gov and follow CONSORT guidelines for reporting. Use adaptive trial designs (e.g., Bayesian adaptive randomization, seamless Phase II/III) when appropriate to improve efficiency.
References
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry. Journal of Health Economics , 47, 20-33.
Lipinski, C. A. (2004). Lead- and drug-like compounds. Advanced Drug Delivery Reviews , 56(3), 215-217.